Heparin-induced thrombocytopenia associated with thrombotic microangiopathy

Hamostaseologie

Volumn 33, Issue 2, 2013, Pages 160-163

  Studt, J D ^a   Binet, I ^b   Nair, G ^a   Schanz, U ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Heparin; Heparin induced thrombocytopenia; HIT; Thrombocytopenia; Thrombotic microangiopathy; TMA

Indexed keywords

CORTICOSTEROID; FRESH FROZEN PLASMA; HEPARIN; IMMUNOGLOBULIN; LEPIRUDIN; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; MALE; PLASMAPHERESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

AGED; ANTICOAGULANTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HEPARIN; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 84881491722     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-03-0012     Document Type: Article

References (29)

1. Alberio L, Kimmerle A, Baumann S et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114: 528-536.
2. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86: 743-751.
3. Douglas KW, Pollock KG, Young D. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apheresis 2010; 25: 47-53.
4. Fontana S, Gerritsen H, Kremer Hovinga J et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001; 113: 100-202.
5. George JN, Terrell DR, Vesely SK et al. Thrombotic microangiopathic syndroms associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med 2012; 41: 177-188.
6. Greinacher A, Althaus K, Krauel K, Selleng S. Heparin- induced thrombocytopenia. Hämostaseologie 2010; 30: 17-28.
7. Greinacher A, Alban S, Omer-Adam MA et al. Heparin- induced thrombocytopenia: a stoichiometry- based model to explain the differing immunogenicities of unfractionated heparin, low molecular weight-heparin, and fondaparinux in different clinical settings. Thromb Res 2008; 122: 211-220.
8. Güngör T, Furlan M, Lämmle B, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology 2001; 40: 940-942.
9. Howard MA, Williams LA, Terrell DR et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: An additional study of 57 consecutive patients, 2002-2005. Transfusion 2006; 46: 154-156.
10. Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007; 19: 148-154.
11. Kokame K, Nobe Y, Kokubo Y et al. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
12. Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res 2010; 125: 292-29
13. Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol 2008; 15: 445-450.
14. Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-1148.
15. Kremer Hovinga JA, Vesely SK, Terrell DR et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115; 1500-1511.
16. Lubenow N, Hinz P, Thomaschewski et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797-1803.
17. McMinn JR, Thomas IA, Terrell DR et al. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 2003; 43: 415.
18. Moake JL. Thrombotic thrombocytopenia purpura and other thrombotic microangiopathies. Best Pract Res Clin Haematol 2009; 22: 567-576.
19. Nellen V, Sulzer I, Barizzi G et al. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1291 patients. Haematologica 2012; 97: 98.
20. Nguyen L, Terrell DR, Duvall D et al. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009; 49: 394.
21. Rizv MA, Vesely SK, George JN. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40: 896-901.
22. Schaller M, Sulzer I, Mansouri M et al. Anti- ADAMTS13 inhibitor boosting during plasma exchange therapy in acquired TTP as a result of a general dysregulation of the immune response. Hämostaseologie 2012; 32: A18.
23. Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335.
24. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-555.
25. Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry- based model of immunization. J Thromb Haemost 2010; 8: 504-512.
26. Warkentin TE, Greinacher A, Gruel Y et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9: 2498-2500.
27. Warkentin TE, Levine MN, Hirsh J et al. Heparininduced thrombocytopenia in patients treated with low-molecular-weight-heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
28. Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708.
29. Yagi H, Konno M, Kinoshita S et al. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol 2001; 115: 991-997.